PureTech Health (PRTC) Stock Forecast, Price Target & Predictions
PRTC Stock Forecast
PureTech Health stock forecast is as follows: an average price target of $57.00 (represents a 162.67% upside from PRTC’s last price of $21.70) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PRTC Price Target
The average price target for PureTech Health (PRTC) is $57.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $44.00. This represents a potential 162.67% upside from PRTC's last price of $21.70.
PRTC Analyst Ratings
According to 2 Wall Street analysts, PureTech Health's rating consensus is 'Buy'. The analyst rating breakdown for PRTC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PureTech Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 25, 2022 | Edward Tenthoff | Piper Sandler | $44.00 | $30.50 | 44.26% | 102.76% |
| Aug 09, 2022 | - | Leerink Partners | $70.00 | $27.52 | 154.36% | 222.58% |
| Jun 15, 2022 | - | Leerink Partners | $66.00 | $19.50 | 238.46% | 204.15% |
| Jun 14, 2022 | Edward Tenthoff | Piper Sandler | $37.00 | $19.50 | 89.74% | 70.51% |
The latest PureTech Health stock forecast, released on Aug 25, 2022 by Edward Tenthoff from Piper Sandler, set a price target of $44.00, which represents a 44.26% increase from the stock price at the time of the forecast ($30.50), and a 102.76% increase from PRTC last price ($21.70).
PureTech Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $21.70 | $21.70 | $21.70 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of PureTech Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PureTech Health's last price of $21.70. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 25, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 09, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jun 15, 2022 | SVB Leerink | Outperform | Outperform | Hold |
PureTech Health's last stock rating was published by Piper Sandler on Aug 25, 2022. The company gave PRTC a "Overweight" rating, the same as its previous rate.
PureTech Health Financial Forecast
PureTech Health Revenue Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | $143.63K | $7.50M | $6.00M |
| High Forecast | $143.63K | $7.50M | $6.00M |
| Low Forecast | $143.63K | $7.50M | $6.00M |
| # Analysts | 1 | 1 | 1 |
| Surprise % | - | - | - |
PureTech Health's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRTC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PureTech Health EBITDA Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EBITDA | - | - | - |
| Avg Forecast | $-28.73K | $-1.50M | $-1.20M |
| High Forecast | $-28.73K | $-1.50M | $-1.20M |
| Low Forecast | $-28.73K | $-1.50M | $-1.20M |
| Surprise % | - | - | - |
undefined analysts predict PRTC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PureTech Health's previous annual EBITDA (undefined) of $NaN.
PureTech Health Net Income Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| Net Income | - | - | - |
| Avg Forecast | $415.65M | $-817.06M | $-876.38M |
| High Forecast | $415.65M | $-817.06M | $-876.38M |
| Low Forecast | $415.65M | $-817.06M | $-876.38M |
| Surprise % | - | - | - |
PureTech Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRTC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PureTech Health SG&A Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| SG&A | - | - | - |
| Avg Forecast | $1.00M | $52.35M | $41.88M |
| High Forecast | $1.00M | $52.35M | $41.88M |
| Low Forecast | $1.00M | $52.35M | $41.88M |
| Surprise % | - | - | - |
PureTech Health's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRTC last annual SG&A of $NaN (undefined).
PureTech Health EPS Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EPS | - | - | - |
| Avg Forecast | $1.54 | $-3.03 | $-3.25 |
| High Forecast | $1.54 | $-3.03 | $-3.25 |
| Low Forecast | $1.54 | $-3.03 | $-3.25 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, PureTech Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRTC previous annual EPS of $NaN (undefined).
PureTech Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| OPT | Opthea | $3.28 | $14.00 | 326.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ACRV | Acrivon Therapeutics | $6.50 | $21.83 | 235.85% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| PRTC | PureTech Health | $21.70 | $57.00 | 162.67% | Buy |
| NUVB | Nuvation Bio | $2.58 | $6.75 | 161.63% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| JANX | Janux Therapeutics | $48.96 | $61.20 | 25.00% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |